Alopecia areata. Diagnostic and therapeutic recommendations
of the Polish Society of Dermatology. Part 2: Treatment

Adriana Rakowska; Lidia Rudnicka; Małgorzata Olszewska; Beata Bergler-Czop; Joanna Czuwara; Ligia Brzezińska-Wcisło; Joanna Narbutt; Waldemar Placek; Barbara Zegarska

doi:10.5114/dr.2023.127705

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2023
vol. 110

Send email

Copy url:

abstract:

Special paper

Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment

Adriana Rakowska

¹

,

Lidia Rudnicka

¹

,

Małgorzata Olszewska

¹

,

Beata Bergler-Czop

²

,

Joanna Czuwara

¹

,

Ligia Brzezińska-Wcisło

²

,

Joanna Narbutt

³

,

Waldemar Placek

⁴

,

Barbara Zegarska

⁵

Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
Department of Dermatology, Medical University of Silesia, Katowice, Poland
Department of Dermatology, Pediatric and Oncological Dermatology, Medical University of Lodz, Lodz, Poland
Department of Dermatology, Sexually Transmitted Diseases and Immunology, University of Warmia and Mazury, Olsztyn, Poland
Department of Cosmetology and Aesthetic Dermatology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

Dermatol Rev/Przegl Dermatol 2023, 110, 101–120

DOI: https://doi.org/10.5114/dr.2023.127705

Online publish date: 2023/05/26

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Rakowska A, Rudnicka L, Olszewska M, et al. Alopecia areata. Diagnostic and therapeutic recommendations
of the Polish Society of Dermatology. Part 2: Treatment. Dermatology Review/Przegląd Dermatologiczny. 2023;110(2):101-120. doi:10.5114/dr.2023.127705.

APA

Rakowska, A., Rudnicka, L., Olszewska, M., Bergler-Czop, B., Czuwara, J.,  & Brzezińska-Wcisło, L. et al. (2023). Alopecia areata. Diagnostic and therapeutic recommendations
of the Polish Society of Dermatology. Part 2: Treatment. Dermatology Review/Przegląd Dermatologiczny, 110(2), 101-120. https://doi.org/10.5114/dr.2023.127705

Chicago

Rakowska, Adriana, Lidia Rudnicka, Małgorzata Olszewska, Beata Bergler-Czop, Joanna Czuwara, Ligia Brzezińska-Wcisło,  and Joanna Narbutt et al. 2023. "Alopecia areata. Diagnostic and therapeutic recommendations
of the Polish Society of Dermatology. Part 2: Treatment". Dermatology Review/Przegląd Dermatologiczny 110 (2): 101-120. doi:10.5114/dr.2023.127705.

Harvard

Rakowska, A., Rudnicka, L., Olszewska, M., Bergler-Czop, B., Czuwara, J., Brzezińska-Wcisło, L., Narbutt, J., Placek, W.,  and Zegarska, B. (2023). Alopecia areata. Diagnostic and therapeutic recommendations
of the Polish Society of Dermatology. Part 2: Treatment. Dermatology Review/Przegląd Dermatologiczny, 110(2), pp.101-120. https://doi.org/10.5114/dr.2023.127705

MLA

Rakowska, Adriana et al. "Alopecia areata. Diagnostic and therapeutic recommendations
of the Polish Society of Dermatology. Part 2: Treatment." Dermatology Review/Przegląd Dermatologiczny, vol. 110, no. 2, 2023, pp. 101-120. doi:10.5114/dr.2023.127705.

Vancouver

Rakowska A, Rudnicka L, Olszewska M, Bergler-Czop B, Czuwara J, Brzezińska-Wcisło L et al. Alopecia areata. Diagnostic and therapeutic recommendations
of the Polish Society of Dermatology. Part 2: Treatment. Dermatology Review/Przegląd Dermatologiczny. 2023;110(2):101-120. doi:10.5114/dr.2023.127705.

PlumX metrics:

The treatment goal in alopecia areata is induction of hair regrowth and halting the progression of the disease. Treatment decisions depend on the severity of the alopecia areata as assessed by the Severity of Alopecia Tool (SALT) or the Alopecia Areata Scale (AAS). In mild alopecia areata, very ultra-high potency topical glucocorticoids and intralesional triamcinolone acetonide are the mainstay of treatment. In moderate to severe alopecia areata, systemic treatment is usually required. Currently, the only drug dedicated for alopecia areata, approved in Europe and the United States is baricitinib. Ritlecitinib, a JAK3/TEC inhibitor is approved in the United States for individuals 12 years of age and older with severe alopecia areata and is expected to be approved in Europe soon. Other systemic medications used in alopecia areata include glucocorticoids, cyclosporine, and methotrexate. Contact immunotherapy may be considered. In alopecia areata, long-maintenance treatment is of substantial significance.

keywords:

alopecia areata, baricitinib, biological treatment, contact immunotherapy, cyclosporine, deuruxolitinib, JAK inhibitors, methotrexate, glucocorticoids, ritlecitinib , treatment, triamcinolone acetonide

Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment

Adriana Rakowska 1 , Lidia Rudnicka 1 , Małgorzata Olszewska 1 , Beata Bergler-Czop 2 , Joanna Czuwara 1 , Ligia Brzezińska-Wcisło 2 , Joanna Narbutt 3 , Waldemar Placek 4 , Barbara Zegarska 5

alopecia areata, baricitinib, biological treatment, contact immunotherapy, cyclosporine, deuruxolitinib, JAK inhibitors, methotrexate, glucocorticoids, ritlecitinib , treatment, triamcinolone acetonide

Adriana Rakowska

¹

,

Lidia Rudnicka

¹

,

Małgorzata Olszewska

¹

,

Beata Bergler-Czop

²

,

Joanna Czuwara

¹

,

Ligia Brzezińska-Wcisło

²

,

Joanna Narbutt

³

,

Waldemar Placek

⁴

,

Barbara Zegarska

⁵